|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 6.205 USD | -12.23% |
|
+0.89% | +182.05% |
| Dec. 09 | Immix Biopharma announces closing of upsized $100 million underwritten offering of common stock and pre-funded warrants | RE |
| Dec. 08 | Immix Biopharma Prices $100 Million Offering | MT |
Company Valuation: Immix Biopharma, Inc.
Data adjusted to current consolidation scope
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|
| Capitalization 1 | 47.02 | 31.89 | 137.5 | 60.52 | 208.2 | - |
| Change | - | -32.18% | 331.07% | -55.98% | 244.01% | - |
| Enterprise Value (EV) 1 | 47.02 | 18.46 | 120 | 60.52 | 215.5 | 194 |
| Change | - | -60.75% | 550.03% | -49.56% | 256.09% | -9.98% |
| P/E ratio | -0.54x | -3.88x | -7.78x | -2.89x | -8x | -9.05x |
| PBR | - | - | - | - | - | - |
| PEG | - | 0x | -0.2x | 0.2x | -4.05x | 0.8x |
| Capitalization / Revenue | - | - | - | - | - | - |
| EV / Revenue | - | - | - | - | - | - |
| EV / EBITDA | - | -2.25x | -7.44x | - | -8.36x | -7.98x |
| EV / EBIT | - | -2.25x | -7.43x | -2.67x | -8.15x | -6.35x |
| EV / FCF | - | - | - | - | - | - |
| FCF Yield | - | - | - | - | - | - |
| Dividend per Share 2 | - | - | - | - | - | - |
| Rate of return | - | - | - | - | - | - |
| EPS 2 | -6.64 | -0.59 | -0.89 | -0.76 | -0.775 | -0.685 |
| Distribution rate | - | - | - | - | - | - |
| Net sales 1 | - | - | - | - | - | - |
| EBITDA 1 | - | -8.217 | -16.14 | - | -25.78 | -24.32 |
| EBIT 1 | - | -8.219 | -16.14 | -22.67 | -26.44 | -30.53 |
| Net income 1 | -24.38 | -8.23 | -15.43 | -21.61 | -25.52 | -30.46 |
| Net Debt 1 | - | -13.44 | -17.51 | - | 7.31 | -14.21 |
| Reference price 2 | 3.560 | 2.290 | 6.920 | 2.200 | 6.200 | 6.200 |
| Nbr of stocks (in thousands) | 13,209 | 13,927 | 19,867 | 27,508 | 33,578 | - |
| Announcement Date | 3/28/22 | 3/27/23 | 3/29/24 | 3/25/25 | - | - |
1USD in Million2USD
Estimates
P/E ratio, Detailed evolution
| P/E (N) | EV / Sales (N) | EV / EBITDA (N) | Dividend Yield (N) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -9.12x | - | -9.49x | - | 237M | |
| 48.77x | 11.89x | 42.72x | -.--% | 54.11B | |
| -31.96x | 81.09x | -35.85x | -.--% | 42.02B | |
| 16.65x | 5.82x | 13.2x | 1.7% | 39.6B | |
| -23.83x | 3.27x | -8.94x | -.--% | 22.8B | |
| 17.26x | 4.24x | 11.37x | -.--% | 19.5B | |
| 28.14x | 5.53x | 15.33x | -.--% | 17.76B | |
| -513.74x | 29.73x | 701.05x | -.--% | 14.73B | |
| -13.59x | 170.75x | -26.62x | -.--% | 13.55B | |
| -192.75x | 45.87x | -186.28x | -.--% | 13.14B | |
| Average | -67.42x | 39.80x | 51.65x | 0.19% | 23.74B | |
| Weighted average by Cap. | -33.86x | 33.27x | 38.48x | 0.28% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
- Stock Market
- Equities
- IMMX Stock
- Valuation Immix Biopharma, Inc.
Select your edition
All financial news and data tailored to specific country editions
